Advanced Solid Tumors
804
188
231
321
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
106 trials with published results (13%)
Research Maturity
321 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.7%
102 terminated out of 804 trials
75.9%
-10.6% vs benchmark
0%
3 trials in Phase 3/4
33%
106 of 321 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 321 completed trials
Clinical Trials (804)
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
A Study of JNJ-87890387 for Advanced Solid Tumors
A Study of PHN-012 in Patients With Advanced Solid Tumors
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
A Study of BG-C477 in Participants With Advanced Solid Tumors
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors